0

Synthesis and Biological Assessment of Racemic Benzochromenopyrimidinimines as Antioxidant, Cholinesterase, and Aβ1-42 Aggregation Inhibitors for Alzheimer's Disease Therapy

Youssef Dgachi, Lhassane Ismaili, Damijan Knez, Mohamed Benchekroun, Hélène Martin, Natalia Szałaj, Sarah Wehle, Oscar M Bautista-Aguilera, Vincent Luzet, Alexandre Bonnet, Barbara Malawska, Stanislav Gobec, etc.

ChemMedChem. 2016 Jun 20;11(12):1318-27.

PMID: 26804623

Abstract:

Given the complex nature of Alzheimer's disease (AD), compounds that are able to simultaneously address two or more AD-associated targets show greater promise for development into drugs for AD therapy. Herein we report an efficient two-step synthesis and biological evaluation of new racemic benzochromene derivatives as antioxidants, inhibitors of cholinesterase and β-amyloid (Aβ1-42 ) aggregation. Based on the results of the primary screening, we identified 15-(3-methoxyphenyl)-9,11,12,15-tetrahydro-10H,14H-benzo[5,6]chromeno[2,3-d]pyrido[1,2-a]pyrimidin-14-imine (3 e) and 16-(3-methoxyphenyl)-9,10,11,12,13,16-hexahydro-15H-benzo[5',6']chromeno[2',3':4,5]pyrimido[1,2-a]azepin-15-imine (3 f) as new potential multitarget-directed ligands for AD therapy. Further in-depth biological analysis showed that compound 3 f is a good human acetylcholinesterase inhibitor [IC50 =(0.36±0.02) μm], has strong antioxidant activity (3.61 μmol Trolox equivalents), and moderate Aβ1-42 antiaggregating power (40.3 %).

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
IAR4248094 Amyloid β 13-16 human Amyloid β 13-16 human Price
qrcode